🇺🇸 FDA
Pipeline program

REGN3918

R3918-PNH-1852

Phase 2 small_molecule completed

Quick answer

REGN3918 for Paroxysmal Nocturnal Hemoglobinuria (PNH) is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Regeneron UK Limited
Indication
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials